Outcome of ANCA-associated primary renal vasculitis in Miyazaki Prefecture

Internal Medicine

Volumn 46, Issue 12, 2007, Pages 815-822

  Uezono, Shigehiro ^a,b   Sato, Yuji ^a   Hara, Seiichiro ^a   Hisanaga, Shuichi ^c   Fukudome, Keiichi ^d   Fujimoto, Shouichi ^a   Nakao, Hiroyuki ^b   Kitamura, Kazuo ^a   Kobayashi, Shigeto ^c   Suzuki, Kazuo ^f   Hashimoto, Hiroshi ^e   Nunoi, Hiroyuki ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c Koga General Hospital   (Japan)

^d Miyazaki Social Insurance Hospital   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

ANCA associated glomerulonephritis; Microscopic polyangiitis; Pauci immune crescentic glomerulonephritis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DIALYSIS; DISEASE DURATION; DRUG PULSE THERAPY; EARLY DIAGNOSIS; EARLY INTERVENTION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTIOUS COMPLICATION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; PRIMARY KIDNEY VASCULITIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENOVASCULAR DISEASE; RISK FACTOR; SURVIVAL RATE;

AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CAUSALITY; CAUSE OF DEATH; COMORBIDITY; DIALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSION; INFECTION; JAPAN; KIDNEY DISEASES; LUNG DISEASES; MALE; PROGNOSIS; SURVIVAL ANALYSIS; VASCULITIS, HYPERSENSITIVITY;

EID: 34547916432     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6371     Document Type: Article

References (29)

1. Fujimoto S, Uezono S, Hisanaga S, et al. Incidence of ANCA-associated primary renal vasculitis in Miyazaki Prefecture: The first population-based, retrospective epidemiological survey in Japan. Clin J Am Soc Nephrol 1: 1016-1022, 2006.
2. Tidman M, Olander R, Svalander C, Danielsson D. Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-1995: organ involvement, ANCA patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med 244: 133-141, 1998.
3. Lane SE, Scott DG, Heaton A, Watts RA. Primary renal vasculitis in Norfolk-increasing incidence or increasing recognition? Nephrol Dial Transplant 15: 23-27, 2000.
4. Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the systemic vasculitides in northwest Spain: Implications of the Chapel Hill Consensus Conference Definitions. Arthritis Rheum 49: 388-393, 2003.
5. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: Results from German vasculitis register. Arthritis Rheum 53: 93-99, 2005.
6. Matsumoto M, Kobayashi S, Hashimoto H, et al. Nationwide epidemiological survey of refractory vasculitis (anti-neutrophil cyto-plasmic antibody (ANCA)-associated vasculitis, anti-phospholipid syndrome and temporal arteritis) in Japan. Annual report of the Research Committee on Intractable Vasculitides, the Ministry of Health and Welfare of Japan 15-23, 1998 (in Japanese).
7. Sakai K, Kurokawa K, Koyama A, et al. Clinical guideline for the rapidly progressive glomerulonephritis in Japan. Jpn J Nephrol 44: 55-82, 2002 (in Japanese).
8. Yamagata K, Hirayama K, Mase K, et al. Apheresis for MPO-ANCA-associated RPGN-indications and efficacy: lessons learned from Japan nationwide survey of RPGN. J Clin Apher 20: 244-251, 2005.
9. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer mobility in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9: 842-852, 1998.
10. Booth AD, Almond MK, Bums A, et al. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am J Kidney Dis 41: 776-784, 2003.
11. Little MA, Nazar L, Farrington K. Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity Nephrol Dial Transplant 19: 356-364, 2004.
12. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 19: 1403-1411, 2004.
13. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century:A disease of older patients. Rheumatology 44: 495-501, 2005.
14. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Glomerular Disease Collaborative Network. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangitis and glomerulonephritis. J Am Soc Nephrol 7: 23-32, 1996.
15. Cohen B, Clark WF. Pauci-immune renal vasculitis: Natural history, prognostic factors, and impact of therapy. Am J. Kidney Dis 36: 914-924, 2000.
16. Jayne DR, Rasmussen N. Treatment of anti-neutrophil cytoplasmic antibody-associated systemic vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trial Study Group. Mayo Clin Proc 72: 737-747, 1997.
17. Jayne DR. European Vasculitis Study Group (EUVAS). Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 13: 48-55, 2001.
18. Hauer HA, Bajema IM, VanHouwelingen HC, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 62: 1732-1742, 2002.
19. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 43: 414-419, 2000.
20. Kaplan-Pavlovcic S, Cerk K, Kveder R, Lindic J, Vizjak A. Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant 18: v5-v7, 2003.
21. Satchell SC, Nicholls AJ, D'Souza RJ, Beaman M. Renal vasculitis: increasing a disease of the elderly? Nephron Clin Prac 97: c142-c146, 2004.
22. Franssen C, Gans R, Kallenberg C, Hageluken C, Hoorntje S. Disease spectrum of patients with antineutrophil cytoplasmic autoanti-bodies of defined specificity: distinct differences between patients with anti-proteinase 3 and anti-myeloperoxidase autoantibodies. J Intern Med 244: 209-216, 1998.
23. Jayne DR. Evidence-based treatment of systemic vasculitis. Rheumatology(Oxford) 39: 585-595, 2000.
24. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36-44, 2003.
25. Wormser GP, Horowitz HW, Duricanson FP, et al. Low-dose intermittent trimethoprim-sulfamethoxazole for prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. Arch Intern Med 151: 688-692, 1991.
26. http://www.vasculitis.org/progress.htm (Update on 22.02.2007).
27. http://www.nanbyou.or.jp/sikkan/025_2_i.htm#07 (Update on 20.10.2006).
28. Falk RJ, Jennette JC. Thoughts about the classification of small vessel vasculitis. J Nephrol 17: 3-9, 2004.
29. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 117: 39-50, 2004.